Carcinosarcomas are rare tumors that comprise microscopic features of both epithelial tumors (carcinomas) and connective tissue tumors (sarcomas). Data about carcinosarcoma are relatively scarce. In this study, data about carcinosarcoma in the SEER’s database were explored and further analyzed and summarized. SEER incorporates clinical and epidemiological data from 18 cancer registries all over the United States and presented data can be extrapolated to generate evidence on this rarely occurring tumor.
SEER*Stat Version 8.3.5 was used to obtain data from the SEER 18 Regs Nov 2017 Submission database. Cases diagnosed between 2000-2015 with carcinosarcoma (ICD-O-3 8980/3, 8981/3) were included. Both SEER*Stat and SPSS were used for further data analysis.
A total of 8365 patients were diagnosed with carcinosarcoma between 2000 and 2015, with a median age of 68. The disease occurred predominantly in females (n = 7578; 90.6%) and was more common in white race (n = 6231; 74.5%). Incidence rate was 6.2 per million (CI: 6.1-6.3) with a significant increase of incidence over time (annual percent change = 6.1%) The most common sites for occurrence were the corpus uteri (n = 4656; 55.7%) and ovary (n = 1100; 13.2%) followed by other part of the female genital system (n = 886; 10.6%). The disease was the only primary tumor in 5969 (71.4%) of cases, and the first of 2 or more primaries in 493 patients (8.3%). It occurred as a second or later multiple primary in the remaining percentage of patients (n = 1903; 22.7%). Median survival was 20.5 months, with 5-years and 10-years observed survival being 30.6% (CI: 29.3-31.9%) and 22.4% (CI: 21-23.8%) respectively. Relative survival at 5 years and 10 years was 34.5% (CI: 33.1-36%) and 29.5% (CI: 27.7-31.3%) respectively.
Carcinosarcoma is a rare tumor that occurs with an incidence rate of 6.2 per million. It is predominantly a disease of females who represents 90.6% of cases with female genital system being the main site of occurrence. The disease occurred as a second (or later) primary in 22.7% of patients. It has a median survival of 20.5 months and a relative 5-years survival of 34.5%.
Clinical trial identification
Legal entity responsible for the study
Mohamed Alaa Gouda.
Has not received any funding.
The author has declared no conflicts of interest.